Tirzepatide Treatment for Weight Loss

About Tirzepatide

Tirzepalde is a prescribed injectable for adults with type 2 diabetes and or obesity aiding in better blood sugar levels when combined with diet and exercise.

Here’s why Tirzepatide stands out:

  • Efficacy: Tirzepatide belongs to a class of medications known as GLP-1 receptor agonists. What sets it apart is its dual action on both the GLP-1 and Gip (glucose-dependent insulinotropic peptide) receptors
  • Blood Sugar Control: Studies have shown that Tirzepatide can significantly reduce HbA1c levels, a key marker of blood sugar control.
  • Weight Loss: Clinical trials have demonstrated substantial weight reduction among patients using this medication.
  • Convenience:It is administered as a subcutaneous injection once a week and works by activating both the GIP and GLP-1 receptors, which are key mediators of insulin secretion and glucose metabolism.


Tirzepatide can help your body both regulate blood sugar and decrease how much food you eat.

How does it work?

Tirzepatide works by activating receptors in the body that help lower blood sugar levels and promole weight loss. It targets both the GLP-1 and GIP receptors.

Tirzepatide influences your body’s hunger hormones.

Tirzepatide’s appetite suppression is associated with its ability to delay gastric emptying. Tailored to your unique needs.

What are benefits of Tirzepatide?

Tirzepatide may improve blood sugar control, aid in weight loss, and potentially reduce cardiovascular risk.

Who can use Tirzepatide?

Tirzepatide is usually prescribed for adults with type 2 diabetes or those facing weight loss challenges.

Side effects using Tirzepatide?

Some common side effects might include nausea, vomiting, or diarrhea. Discuss any concerns during your consultation.

Is Tirzepatide a cure?

Tirzepatide isn’t a cure, but it can assist in managing symptoms and improving health when part of a comprehensive treatment plan..

The FDA approved tirzepatide for the treatment of type-2 diabetes in 2022 and weight loss obesity in 2024.

Tirzepatide is the first and only dual GIP and GLP-1 receptor agonist and recent clinical trials in overweight adults found that tirzepatide significantly improved metabolic health markers, body weight and average blood glucose levels (HgbA1C). A large clinical trial saw an average body weight reduction of 20.9% versus 3.1% weight reduction in the placebo group. At the 15 mg dose, 91% of study participants experienced weight loss of 5% or more and 57% lost more than 20% against their baseline.

Tirzepatide is a glucagon-like peptide-1 (GLP-1) receptor agonist and a glucose-dependent insulinotropic polypeptide (GIP). GLP-1 and GIP are incretins, a group of metabolic hormones released into the bloodstream after eating that ultimately result in a decrease in blood glucose levels through several mechanisms:

  • Stimulate first- and second-phase insulin release from pancreatic beta cells
  • Increases insulin sensitivity (in patients with type 2 diabetes, there is decreased GLP-1 and GIP production)
  • Increase glucose uptake by muscles
  • Decrease of glucose-stimulated glucagon from pancreatic alpha cells
  • Lowering glucose production from the liver and fatty liver
  • Promotes the growth and survival of the pancreatic beta cell and stimulation of adipogenesis
  • Delay in gastric emptying
  • Reduces body weight in patients with type 2 diabetes
  • Decrease in food intake by reducing appetite in three ways:
    1. It stimulates GLP-1 receptors in the brain, resulting in feeling full and dramatically reducing appetite.
    2. It stimulates the GIP receptor, which enhances the effect of GLP-1.
    3. It slows emptying of the stomach, so food stays in the stomach longer, so there is less food available for the addition of new food.

Tirzepatide is highly bound to albumin in the plasma and as such it stays in your circulation a long time. This allows for a once-weekly dosing via subcutaneous administration.

The side effects associated with tirzepatide are similar to those of Wegovy® and Ozempic® -in clinical trials, most were reported as mild and affecting the gastrointestinal system.

The side effects tend to occur after 12 hours and can last up to a few days after the first few injections. Subsequent injections tend to not cause significant side effect.

Some individuals report:

  • Nausea
  • Vomiting
  • Bloating
  • Gas
  • Diarrhea
  • Abdominal pain

In addition, studies to date suggest that tirzepatide may cause mild hypoglycemia but that it is unlikely to cause blood sugar to drop to dangerously low levels. The Boxed Warning include thyroid C-cell tumors.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2. Tirzepatide delays gastric emptying, therefore it has the potential to affect the absorption of concomitantly administered oral medications.